90 results
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
30 May 24
Entry into a Material Definitive Agreement
4:09pm
of $100 million, comprising $70 million upfront and $30 million of R&D funding, option exercise fees of up to $100 million, additional development … , Adaptimmune will receive an upfront exclusivity payment of $70 million, plus $15 million in R&D funding at signing. A further $15 million in R&D funding
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
15 May 24
Adaptimmune Reports Q1 2024 Financial and Business Updates
7:39am
of 2023, resulting in the remaining deferred income for the collaboration being recognized as revenue in March 2023.
Research and development (R&D) expenses … : R&D expenses for the three months ended March 31, 2024, were $35.2 million compared to $25.5 million for the same period in 2023. R&D expenses
8-K
EX-99.1
fh5d cu7yjf
6 Mar 24
Adaptimmune Reports Q4 /Full Year 2023 Financial Results and Business Updates
7:05am
8-K
EX-99.1
w34hbx2 nz
8 Nov 23
Adaptimmune Reports Third Quarter Financial Results and Business Update
7:37am
8-K/A
EX-99.3
1x9wj51eqspw fo
10 Aug 23
Financial Statements and Exhibits
4:05pm
8-K
EX-99.1
3t0zq2s3od7kgxtet
9 Aug 23
Adaptimmune Reports Second Quarter Financial Results and Business Update
7:42am
8-K
EX-99.1
1rg35cyy55fal r9
12 May 23
Adaptimmune Reports First Quarter Financial Results and Business Update
7:36am
424B3
9eydpfffgd87npj rv5i
20 Apr 23
Prospectus supplement
4:32pm
S-4/A
zhamd145i57wt
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
8-K
EX-10.1
00fh3k
11 Apr 23
Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune
8:08am
S-4
mggh8evo19 e7sg
5 Apr 23
Registration of securities issued in business combination transactions
4:40pm